# Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

> **NCT04951362** · PHASE2,PHASE3 · UNKNOWN · sponsor: **South Valley University** · enrollment: 117 (estimated)

## Conditions studied

- Anosmia

## Interventions

- **DRUG:** intranasal spray ivermectin

## Key facts

- **NCT ID:** NCT04951362
- **Lead sponsor:** South Valley University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-20
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-15
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2022-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951362, "Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT04951362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*